Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

271.66 -0.24 (-0.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
The Smartest High-Yielding Dividend Stocks in the Nasdaq Composite Index to Buy With $1,500 Right Now
Via The Motley Fool
Topics Economy Stocks World Trade
Exposures Economy Interest Rates Tariff
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little. 
Via The Motley Fool
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Better Weight Loss Stock: Amgen or Viking Therapeutics?
Via The Motley Fool
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying
The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target. 
Via Investor's Business Daily
What the Options Market Tells Us About Amgen
Via Benzinga
Amgen Unusual Options Activity For May 02
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
Marjorie Taylor Greene Goes Shopping For Tesla, Netflix, UnitedHealth And More: 19 Stocks The Congresswoman Bought
Marjorie Taylor Greene disclosing buying 19 different stocks in a new filing. The buys come less than two weeks after the purchase of 50 different stocks. 
Via Benzinga
2 Safe-and-Steady Stocks Worth Your Attention and 1 to Avoid
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Exposures Political
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
Exposures Product Safety
AMGN Q1 Earnings Call: Product Pipeline and Margin Expansion Drive Outperformance
Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.4% year on year to $8.15 billion. The company expects the full year’s revenue... 
Via StockStory
Topics World Trade
Exposures Tariff
Stock Of The Day: Amgen Slips With Healthcare Sector, But Signals Point To A Reversal
Shares of Amgen (AMGN) have been trending lower with the Health Care sector. But the sell off may soon come to an end. 
Via Benzinga
3 Healthcare Stocks to Research Further
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
Exposures Political
Thursday's session: gap up and gap down stock in the S&P500 index
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
2 Unstoppable Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance. 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Amgen
Via Benzinga
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook and investor caution. 
Via Benzinga
Nasdaq 100 Leads Wall Street Rally As China Signals Openness To Fentanyl Talks, Easing Trade Tensions
U.S. stocks rose on hopes of China's willingness to negotiate a trade deal regarding fentanyl production. Tech stocks led the rally. 
Via Benzinga
Wall Street Eyes 9th Straight Day Of Gains, Apple Falls As Chinese Sales Disappoint: What's Driving Markets Friday?
U.S. stocks advanced across the board by midday Friday, with the S&P 500 eyeing its ninth consecutive day of gains—poised for the longest winning streak since May 2024. 
Via Benzinga
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities. 
Via MarketBeat
Topics Economy World Trade
Exposures COVID-19 Supply Chain Tariff
Amgen’s (NASDAQ:AMGN) Q1: Beats On Revenue
Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2025, with sales up 9.4% year on year to $8.15 billion. The company expects the full year’s revenue to be around $35... 
Via StockStory
Beat the Nasdaq With This Cash-Gushing Dividend Stock
Via The Motley Fool
Topics Economy Stocks
Exposures Economy US Equities
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday?
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully... 
Via Benzinga
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.